|
| |
BioCryst PharmaceuticalsBioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel drugs that block key enzymes essential for viral, cardiovascular and oncologic disease processes. By integrating multiple scientific disciplines - biology, crystallography, medicinal chemistry and computer modeling - BioCryst effectively uses structure-based drug design to discover and develop small-molecule pharmaceuticals.
| Contact Details: |
| 2190 Parkway Lake Drive |
| Birmingham |
| |
| 35244 |
| United States of America |
| Tel: | 205 444 4600 |
| Fax: | 205 444 4640 |
| Email: | info@biocryst.com |
| WWW: | www.biocryst.com/
|
| |
Recent Publications by BioCryst Pharmaceuticals: |  |
Design, parallel synthesis, and crystal structures of biphenyl antithrombotics as selective inhibitors of tissue factor FVIIa complex. Part 1: Exploration of S2 pocket pharmacophores.
Factor VIIa (FVIIa), a serine protease enzyme, coupled with tissue factor... | 9th October, 2009
| BioCryst Pharmaceuticals, Inc., 2190 Parkway Lake Drive, Birmingham, AL
| Bioorg Med Chem. 2009 Jun 1;17(11):3934-58. Epub 2009 Apr 12.
DOI Direct Link |
Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part I.
Forodesine HCl is being investigated as a potential therapeutic target for... | 30th June, 2009
| BioCryst Pharmaceuticals Inc., Birmingham, AL-35244, United States.
| Bioorg Med Chem Lett. 2009 May 15;19(10):2624-6. Epub 2009 Apr 9.
DOI Direct Link |
Synthesis of analogs of forodesine HCl, a human purine nucleoside phosphorylase inhibitor-Part II.
Forodesine HCl is being investigated as a potential therapeutic target for... | 30th June, 2009
| BioCryst Pharmaceuticals Inc., Birmingham, AL 35244, United States.
| Bioorg Med Chem Lett. 2009 May 15;19(10):2627-9. Epub 2009 Apr 9.
DOI Direct Link |
The role of T lymphocytes in rheumatoid arthritis and other autoimmune diseases.
Forodesine HCl is being investigated as a potential therapeutic target for... | 3rd May, 2008
| BioCryst Pharmaceuticals, Inc, Birmingham, AL 35244, USA.
| Arthritis Rheum. 2008 Feb;58(2 Suppl):S53-7.
DOI Direct Link |
Probing the S2 site of factor VIIa to generate potent and selective inhibitors: the structure of BCX-3607 in complex with tissue factor-factor VIIa.
Factor VIIa (FVIIa) is a trypsin-like serine protease in the coagulation... | 7th August, 2007
| BioCryst Pharmaceuticals, 2190 Parkway Lake Drive, Birmingham, AL 35216,
| Acta Crystallogr D Biol Crystallogr. 2007 Jun;63(Pt 6):689-97. Epub 2007
DOI Direct Link |
→View more BioCryst Pharmaceuticals research publications. |
Press Releases on BioCryst Pharmaceuticals:
|
 |
| BioCryst Announces Proposed Public Offering of Common Stock |
17th November, 2009 |
BioCryst Pharmaceuticals, Inc. |
BIRMINGHAM, Ala., Nov. 17 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it is offering to sell, subject to market and other conditions, 5,000,000 shares
|
| BioCryst Receives First Peramivir Order From U.S. Government |
5th November, 2009 |
BioCryst Pharmaceuticals, Inc. |
BIRMINGHAM, Ala., Nov. 5 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced it has received an initial order for 10,000 courses of intravenous (i.v.) peramivir
|
| BioCryst's Partner Shionogi Files for Peramivir Regulatory Approval in Japan |
4th November, 2009 |
BioCryst Pharmaceuticals, Inc. |
BIRMINGHAM, Ala., Nov. 4 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in
|
| BioCryst to Present at Oppenheimer Healthcare Conference |
29th October, 2009 |
BioCryst Pharmaceuticals, Inc. |
BIRMINGHAM, Ala., Oct. 29 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, and Stuart
|
| BioCryst Reports Third Quarter 2009 Financial Results and Provides Corporate Update |
29th October, 2009 |
BioCryst Pharmaceuticals, Inc. |
-- The U.S. Food and Drug Administration (FDA) recently issued an Emergency
Use Authorization (EUA) that allows BioCryst's i.v. peramivir to be used
to treat certain adult
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 11 individuals from BioCryst Pharmaceuticals using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 419 times since April 2007, the link to the organisation's website has been followed 58 times Recent Search Terms used to find this page: biocryst | peramivir BioCryst Pharmacueticals patent | . Search for more companies in Birmingham Search for more companies in This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for BioCryst Pharmaceuticals |
